Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors

被引：35

作者：

Beck, Hilary P. ^{[1
]}

DeGraffenreid, Michael ^{[1
]}

Fox, Brian ^{[1
]}

Allen, John G. ^{[2
]}

Rew, Yosup ^{[1
]}

Schneider, Stephen ^{[3
]}

Saiki, Anne Y. ^{[4
]}

Yu, Dongyin ^{[4
]}

Oliner, Jonathan D. ^{[4
]}

Salyers, Kevin ^{[5
]}

Ye, Qiuping ^{[6
]}

Olson, Steven ^{[1
]}

机构：

[1] Amgen Inc, Chem Res & Discovery, San Francisco, CA 94080 USA

[2] Amgen Inc, Chem Res & Discovery, Thousand Oaks, CA 91320 USA

[3] Amgen Inc, Chem Res & Discovery, Cambridge, MA 02142 USA

[4] Amgen Inc, Oncol Res, Thousand Oaks, CA 91320 USA

[5] Amgen Inc, PKDM, Thousand Oaks, CA 91320 USA

[6] Amgen Inc, PKDM, San Francisco, CA 94080 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 09期

关键词：

Oncology; Protein-protein interaction; Pharmacokinetics; SMALL-MOLECULE INHIBITORS; CANCER-THERAPY; P53; AMPLIFICATION; APOPTOSIS; STABILITY; BINDING;

D O I：

10.1016/j.bmcl.2010.11.027

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Human murine double minute 2 (MDM2) is a negative regulator of p53, which plays an important role in cell cycle and apoptosis. We report several optimizations to the synthesis of the chromenotriazolopyrimidine series of MDM2-p53 protein-protein interaction inhibitors. Additionally, the in vitro and in vivo stability, pharmacokinetic properties and solubility were improved through N-substitution. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：2752 / 2755

页数：4

共 50 条

[21] Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges
Wang, Shaomeng
Zhao, Yujun
Aguilar, Angelo
Bernard, Denzil
Yang, Chao-Yie
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2017, 7 (05):
[22] Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
Shangary, Sanjeev
Wang, Shaomeng
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2009, 49 : 223 - 241
[23] The development of piperidinones as potent MDM2-P53 protein - protein interaction inhibitors for cancer therapy
Liao, Guochao
Yang, Deying
Ma, Leilei
Li, Wenwei
Hu, Liqin
Zeng, Liming
Wu, Peng
Duan, Lixin
Liu, Zhongqiu
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 159 : 1 - 9
[24] Small molecule protein-protein inhibitors for the p53-MDM2 interaction
Dudkina, Anna S.
Lindsley, Craig W.
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (10) : 952 - 960
[25] Design and synthesis of non-peptidic a-helix mimics targeting for MDM2-p53 protein-protein interaction
Zhou, Mingzhou
Topper, Melissa E.
Anderson, Laura
McLaughlin, Jillian M.
Santiago, Daniel N.
Fronczek, Frank R.
Guida, Wayne C.
McLaughlin, Mark L.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 239
[26] Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity
Brandao, Pedro
Loureiro, Joana B.
Carvalho, Sylvie
Hamadou, Meriem Hadjer
Cravo, Sara
Moreira, Joana
Pereira, Daniela
Palmeira, Andreia
Pinto, Madalena
Saraiva, Lucilia
Cidade, Honorina
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 156 : 711 - 721
[27] A facile method to screen inhibitors of protein-protein interactions including MDM2-p53 displayed on T7 phage
Ishi, Kazutomo
Sugawara, Fumio
BIOCHEMICAL PHARMACOLOGY, 2008, 75 (09) : 1743 - 1750
[28] Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction
Gureev, Maxim
Novikova, Daria
Grigoreva, Tatyana
Vorona, Svetlana
Garabadzhiu, Alexander
Tribulovich, Vyacheslav
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2020, 34 (01) : 55 - 70
[29] Optimization beyond AMG 232: Discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction
Wang, Yingcai
Zhu, Jiang
Liu, Jiwen
Chen, Xiaoqi
Mihalic, Jeff
Deignan, Jeffrey
Yu, Ming
Sun, Daqing
Kayser, Frank
McGee, Lawrence R.
Lo, Mei-Chu
Chen, Ada
Zhou, Jing
Ye, Qiuping
Huang, Xin
Long, Alexander M.
Yakowec, Peter
Oliner, Jonathan D.
Olson, Steven H.
Medina, Julio C.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (16) : 3782 - 3785
[30] Design and preclinical pharmacological evaluation of a cleavable succinate ester solubilizing group for isoindolinone MDM2-p53 protein-protein interaction inhibitors
Zhao, Yan
Thomas, Huw
Liu, Junfeng
Blackburn, Timothy J.
Cully, Sarah
Watson, Anna F.
Hardcastle, Ian R.
Golding, Bernard T.
Griffin, Roger J.
Lunec, John
Newell, David R.
CANCER RESEARCH, 2012, 72

← 1 2 3 4 5 →